Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy

Diabetes Care

Volumn 33, Issue 7, 2010, Pages 1567-1572

  Lajer, Maria ^a   Jorsal, Anders ^a   Tarnow, Lise ^a   Parving, Hans Henrik ^b,c   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN A1C;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROL GROUP; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PROSPECTIVE STUDY; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; ALBUMINURIA; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77958161566     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2174     Document Type: Article

References (25)

1. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996;313: 779-784
2. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000;5: 167-173
3. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D, Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-3072 (Pubitemid 35440290)
4. Selvetella G, Hirsch E, Notte A, Tarone G, Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 2004;63:373-380
5. Azhar M, Schultz Jel J, Grupp I, Dorn GW 2nd, Meneton P, Molin DG, Gittenberger- de Groot AC, Doetschman T. Transforming growth factor beta in cardiovascular development and function. Cytokine Growth Factor Rev 2003;14: 391-407
6. Molkentin JD. A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest 2003;111:1275-1277
7. Strelau J, Böttner M, Lingor P, Suter-Crazzolara C, Galter D, Jaszai J, Sullivan A, Schober A, Krieglstein K, Unsicker K. GDF-15/MIC-1: a novel member of the TGF-beta superfamily. J Neural Transm 2000;(Suppl. 2):273-276
8. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;94: 11514-11519
9. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-360
10. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006;98:342-350
11. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, Metz J, Kinscherf R. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 2004; 318:325-333
12. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T, Ridker PM. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002;359:2159-2163
13. Kempf T, Björklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. Growth-differentiation factor-15 improves risk stratification in STsegment elevation myocardial infarction. Eur Heart J 2007;28:2858-2865
14. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115:962-971
15. Tarnow L, Groop PH, Hadjadj S, Kazeem G, Cambien F, Marre M, Forsblom C, Parving HH, Trégouët D, Thévard A, Farrall M, Gut I, Gauguier D, Cox R, Matsuda F, Lathrop M, Vionnet N, EURAGEDIC Consortium. European rational approach for the genetics of diabetic complications - EURAGEDIC: patient populations and strategy. Nephrol Dial Transplant 2008; 23:161-168
16. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976;36: 35-43
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266
18. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, Drexler H, Johnston N, Wallentin L, Wollert KC. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007;53:284-291
19. Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma Nterminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 2005; 48:149-155
20. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci US A 1997; 94:14730-14735
21. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-1604
22. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71:548-554
23. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48: 156-163
24. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H, Wallentin L. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007;116:1540-1548
25. Preusch MR, Strelau J, Baeuerle M, Blessing E, Bischof M, Kinscherf R, Unsicker K, Katus HA, Bea F. Bone marrow derived growth differentiation factor-15 (GDF-15) protects from macrophage accumulation and effects atherosclerotic lesion stabilisation in low-density lipoprotein receptor-null mice. Circulation 2008; 118:S511-S512